Navigation Links
MINILITH® SL1

ProductsMINILITH® SL1
Company KARL STORZ Endoscopy-America, Inc.
Item MINILITH® SL1
Features 
  • Transportable Lithotripter for the entire range of applications in orthopaedic shock wave Therapy
  • Flexible cylindrical electromagnetic shock wave source
  • In-line ultrasound imaging
Description The MINILITH SL1 developed by STORZ MEDICAL is the result of many years of extensive experience in the field of kidney stone lithotripsy and the successful implementation of the specific requirements to be met by orthopaedic apparatus for extracorporeal shock wave therapy, as has been outlined above. The MINILITH SL1 is characterized by its compact size and astonishing mobility, which allow the system to be transferred to different locations. The apparatus simply has to be plugged in and does not require any further installation procedures.
Info KARL STORZ Endoscopy-America, Inc.
Customer Service: (800) 421-0837
Web site: http://www.karlstorz.com

Related medicine products :

1. Dornier Medilas D Fibertom Endovenous Laser Treatment
2. Dornier Holmium Laser for Urological Procedures
3. Dornier Lithotripter S II
4. Dornier Compact Delta
5. Compact Ultrasonic Phacoemulsification System
6. Oculus Easyfield Compact Perimeter
7. Compact 30C CO2 Lasers
8. Compact 40C CO2 Lasers
9. Veris Compact
10. Compact KTP laser
11. Veris Compact™
Breaking Medicine Technology:Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4For Millions With Untreated Hearing Loss Holiday Season Can be Especially Difficult 6542 1For Millions With Untreated Hearing Loss Holiday Season Can be Especially Difficult 6542 2Crosstalk between critical cell signaling pathways holds clues to tumor invasion and metastasis 62132 1Crosstalk between critical cell signaling pathways holds clues to tumor invasion and metastasis 62132 2Crosstalk between critical cell signaling pathways holds clues to tumor invasion and metastasis 62132 3Tailor made HIV AIDS treatment closer to reality 62127 1Tailor made HIV AIDS treatment closer to reality 62127 2